These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 16823893)

  • 1. Array CGH profiling of favourable histology Wilms tumours reveals novel gains and losses associated with relapse.
    Natrajan R; Williams RD; Hing SN; Mackay A; Reis-Filho JS; Fenwick K; Iravani M; Valgeirsson H; Grigoriadis A; Langford CF; Dovey O; Gregory SG; Weber BL; Ashworth A; Grundy PE; Pritchard-Jones K; Jones C
    J Pathol; 2006 Sep; 210(1):49-58. PubMed ID: 16823893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amplification and overexpression of CACNA1E correlates with relapse in favorable histology Wilms' tumors.
    Natrajan R; Little SE; Reis-Filho JS; Hing L; Messahel B; Grundy PE; Dome JS; Schneider T; Vujanic GM; Pritchard-Jones K; Jones C
    Clin Cancer Res; 2006 Dec; 12(24):7284-93. PubMed ID: 17189400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis by array CGH of genomic changes associated with the progression or relapse of Wilms' tumour.
    Natrajan R; Little SE; Sodha N; Reis-Filho JS; Mackay A; Fenwick K; Ashworth A; Perlman EJ; Dome JS; Grundy PE; Pritchard-Jones K; Jones C
    J Pathol; 2007 Jan; 211(1):52-9. PubMed ID: 17103382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gain of 1q is associated with adverse outcome in favorable histology Wilms' tumors.
    Hing S; Lu YJ; Summersgill B; King-Underwood L; Nicholson J; Grundy P; Grundy R; Gessler M; Shipley J; Pritchard-Jones K
    Am J Pathol; 2001 Feb; 158(2):393-8. PubMed ID: 11159177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chromosomal anomalies at 1q, 3, 16q, and mutations of SIX1 and DROSHA genes underlie Wilms tumor recurrences.
    Spreafico F; Ciceri S; Gamba B; Torri F; Terenziani M; Collini P; Macciardi F; Radice P; Perotti D
    Oncotarget; 2016 Feb; 7(8):8908-15. PubMed ID: 26802027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complex patterns of chromosome 9 alterations including the p16INK4a locus in Wilms tumours.
    Natrajan R; Warren W; Messahel B; Reis-Filho JS; Brundler MA; Dome JS; Grundy PE; Vujanic G; Pritchard-Jones K; Jones C
    J Clin Pathol; 2008 Jan; 61(1):95-102. PubMed ID: 17369505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delineation of a 1Mb breakpoint region at 1p13 in Wilms tumors by fine-tiling oligonucleotide array CGH.
    Natrajan R; Williams RD; Grigoriadis A; Mackay A; Fenwick K; Ashworth A; Dome JS; Grundy PE; Pritchard-Jones K; Jones C
    Genes Chromosomes Cancer; 2007 Jun; 46(6):607-15. PubMed ID: 17370329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular profiling reveals frequent gain of MYCN and anaplasia-specific loss of 4q and 14q in Wilms tumor.
    Williams RD; Al-Saadi R; Natrajan R; Mackay A; Chagtai T; Little S; Hing SN; Fenwick K; Ashworth A; Grundy P; Anderson JR; Dome JS; Perlman EJ; Jones C; Pritchard-Jones K
    Genes Chromosomes Cancer; 2011 Dec; 50(12):982-95. PubMed ID: 21882282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic profiling of chromosome 1 in breast cancer: mapping of regions of gains and losses and identification of candidate genes on 1q.
    Orsetti B; Nugoli M; Cervera N; Lasorsa L; Chuchana P; Rougé C; Ursule L; Nguyen C; Bibeau F; Rodriguez C; Theillet C
    Br J Cancer; 2006 Nov; 95(10):1439-47. PubMed ID: 17060936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group.
    Grundy PE; Breslow NE; Li S; Perlman E; Beckwith JB; Ritchey ML; Shamberger RC; Haase GM; D'Angio GJ; Donaldson M; Coppes MJ; Malogolowkin M; Shearer P; Thomas PR; Macklis R; Tomlinson G; Huff V; Green DM;
    J Clin Oncol; 2005 Oct; 23(29):7312-21. PubMed ID: 16129848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allele loss at 16q defines poorer prognosis Wilms tumour irrespective of treatment approach in the UKW1-3 clinical trials: a Children's Cancer and Leukaemia Group (CCLG) Study.
    Messahel B; Williams R; Ridolfi A; A'hern R; Warren W; Tinworth L; Hobson R; Al-Saadi R; Whyman G; Brundler MA; Kelsey A; Sebire N; Jones C; Vujanic G; Pritchard-Jones K;
    Eur J Cancer; 2009 Mar; 45(5):819-26. PubMed ID: 19231157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative genomic hybridization analysis of Wilms tumors.
    Steenman M; Redeker B; de Meulemeester M; Wiesmeijer K; Voûte PA; Westerveld A; Slater R; Mannens M
    Cytogenet Cell Genet; 1997; 77(3-4):296-303. PubMed ID: 9284942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening for submicroscopic chromosomal rearrangements in Wilms tumor using whole-genome microarrays.
    Rassekh SR; Chan S; Harvard C; Dix D; Qiao Y; Rajcan-Separovic E
    Cancer Genet Cytogenet; 2008 Apr; 182(2):84-94. PubMed ID: 18406869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytogenetic abnormalities and clinical outcome in Wilms tumor: a study by the U.K. cancer cytogenetics group and the U.K. Children's Cancer Study Group.
    Bown N; Cotterill SJ; Roberts P; Griffiths M; Larkins S; Hibbert S; Middleton H; Kelsey A; Tritton D; Mitchell C
    Med Pediatr Oncol; 2002 Jan; 38(1):11-21. PubMed ID: 11835232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gain of 1q is associated with inferior event-free and overall survival in patients with favorable histology Wilms tumor: a report from the Children's Oncology Group.
    Gratias EJ; Jennings LJ; Anderson JR; Dome JS; Grundy P; Perlman EJ
    Cancer; 2013 Nov; 119(21):3887-94. PubMed ID: 23983061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of limited regions of genetic aberrations in patients affected with Wilms' tumor using a tiling-path chromosome 22 array.
    Benetkiewicz M; Díaz de Ståhl T; Gördör A; Pfeifer S; Wittmann S; Gessler M; Dumanski JP
    Int J Cancer; 2006 Aug; 119(3):571-8. PubMed ID: 16496407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Chromosome 1q Gain With Inferior Survival in Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group.
    Gratias EJ; Dome JS; Jennings LJ; Chi YY; Tian J; Anderson J; Grundy P; Mullen EA; Geller JI; Fernandez CV; Perlman EJ
    J Clin Oncol; 2016 Sep; 34(26):3189-94. PubMed ID: 27400937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 16q heterozygosity loss in Wilms' tumour in children and its clinical importance.
    Skotnicka-Klonowicz G; Rieske P; Bartkowiak J; Szymik-Kantorowicz S; Daszkiewicz P; Debiec-Rychter M
    Eur J Surg Oncol; 2000 Feb; 26(1):61-6. PubMed ID: 10718182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathologic correlates of loss of heterozygosity in Wilm's tumor: a preliminary analysis.
    Grundy P; Telzerow P; Moksness J; Breslow NE
    Med Pediatr Oncol; 1996 Nov; 27(5):429-33. PubMed ID: 8926924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative genomic hybridization and its application to Wilms' tumorigenesis.
    Getman ME; Houseal TW; Miller GA; Grundy PE; Cowell JK; Landes GM
    Cytogenet Cell Genet; 1998; 82(3-4):284-90. PubMed ID: 9858837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.